ESBL / MDR Enterobacter
The Enterobacter cloacae complex (ECC) is a leading nosocomial, ESKAPE-class Gram-negative pathogen that causes bloodstream, respiratory, urinary, and device-associated infections, and is increasingly carbapenem-resistant via AmpC/ESBL beta-lactamases and carbapenemases, leaving few or no reliable antibiotics. Because lytic bacteriophages kill bacteria through a mechanism entirely independent of antibiotic resistance, they retain potency against multidrug-resistant (MDR) and carbapenem-resistant ECC isolates that defeat last-line drugs. Phages are self-amplifying, highly specific, can be combined into cocktails to broaden host range and suppress resistance, and penetrate biofilms on catheters and other indwelling devices where ECC is hard to eradicate. This combination of preserved activity against pan-resistant strains, biofilm penetration, and synergy with antibiotics makes phage therapy a strong rational fit for MDR ECC.
How phages act here
Mechanism
Lytic ECC phages adsorb to specific surface receptors and lyse the cell from within, independent of any antibiotic-resistance pathway. Host range is strain-specific, so cocktails are assembled from phages that use distinct receptors to maximize coverage and lower the odds of resistance escape: in characterized ECC phages, the outer-membrane protein OmpA has been identified as a receptor (Fu et al. 2025), and the Entelli-02 cocktail deliberately combines five phages targeting distinct cell-surface receptors to reach 88% coverage of a 206-isolate hospital collection (Subedi et al. 2025). Phages also degrade and penetrate ECC/E. hormaechei biofilms on silicone and latex urological catheters, with several phages encoding depolymerase/lytic regions that disrupt the biofilm matrix (Cieslik et al. 2025). Phage-antibiotic synergy (PAS) further enhances killing of MDR Gram-negative ESKAPE strains including Enterobacter, and dose- and timing-optimized regimens (including prophylactic-plus-therapeutic schedules) markedly improve in vivo efficacy in bacteremia models.
Where it stands
Current evidence
As of 2026 the evidence for ECC specifically is strong at the preclinical/translational stage and emerging at the clinical/therapeutic-product stage; there is not yet a published randomized controlled trial reading out for this exact indication. The landmark advance is Entelli-02 (Subedi, Barr, Peleg et al., Nature Microbiology 2025), a rationally designed, hospital-specific 5-phage cocktail built from The Alfred Hospital (Melbourne) outbreak isolate bank, reaching 88% coverage of 206 ECC isolates and reducing bacterial load by >99% in septicemic mice, manufactured as a therapeutic-grade product 'ready for clinical use.' Independent groups have validated efficacy in animal models: Kuo et al. (Microbiology Spectrum 2025) isolated 12 strictly lytic phages against carbapenem-resistant ECC, with CYPEBC012 lysing 93.75% of 80 CR-ECC isolates and giving 100% early and 80% day-7 survival in a murine bacteremia model; Fu et al. (Antimicrobial Agents and Chemotherapy 2025) showed a 3-phage cocktail (OmpA-receptor-using) rescued mice from carbapenem-resistant ECC bacteremia with clear dose- and timing-dependence. Clinically, ECC patients have been treated under compassionate/expanded-access frameworks (e.g., UCSD IPATH) rather than via a dedicated registered ECC trial; most published human phage cases involve other species, so direct ECC patient outcome data remain limited.
Evidence confidence: medium
The data
Key studies & trials
- Subedi D, Gordillo Altamirano F, Deehan R, Perera A, Patwa R, Kostoulias X, Korneev D, Blakeway L, Macesic N, Peleg AY, Barr JJ. Rational design of a hospital-specific phage cocktail to treat Enterobacter cloacae complex infections. Nature Microbiology. 2025;10(11):2702-2719. ↗
- Kuo HY, Bregente CJB, Thuy TTD, Hidrosollo JH, Cruz-Papa DMD, Gutierrez TA, Huang YT, Chuang YJ, Hsueh PR, Kao CY. Isolation and characterization of strictly lytic bacteriophages against carbapenem-resistant Enterobacter cloacae complex. Microbiology Spectrum. 2025;13(11):e0083525. ↗
- Fu SY, Chen XZ, Yi PC, Gao J, Wang WX, Gu SL, Gao JH, Liu DX, Xu HF, Zeng Y, Hu CM, Zheng Q, Chen W. Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing. Antimicrobial Agents and Chemotherapy. 2025;69(4):e0168324. ↗
- Cieslik M, Wojcicki M, Migdal P, Grygiel I, Bajrak O, Orwat F, Gorski A, Jonczyk-Matysiak E. Fighting biofilm: bacteriophages eliminate biofilm formed by multidrug-resistant Enterobacter hormaechei on urological catheters. Medical Microbiology and Immunology. 2025;214(1):33. ↗
Who is working on it
Programs & centers
The possibility
The arrival of a manufacturing-ready, hospital-specific cocktail like Entelli-02 points to a near future where a hospital facing an MDR Enterobacter outbreak can pull a pre-validated, on-shelf phage product matched to its own circulating strains and treat patients within hours rather than months. Pairing rapid receptor-resolved cocktail design with phage-antibiotic synergy and dose/timing optimization could turn today's untreatable carbapenem-resistant ECC bacteremias and catheter biofilm infections into routinely curable conditions. As regulatory pathways for personalized phage products mature, ECC may become one of the first proving grounds for adaptive, institution-tailored 'living antibiotics.'